Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
30.09.2022 - TORONTO and HOUSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the .
Medicenna Therapeutics Corp. (NASDAQ:NASDAQ:MDNA) Q1 2023 Earnings Conference Call August 15, 2022, 08:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant -.